Pharmas whacked by Trump
CSL, Mayne Pharma and Mesoblast closed lower after Trump accused the sector of “getting away with murder”.
Csl
CSL lifts on European drug tick
CSL will launch a new haemophilia treatment in Europe in coming months, after gaining regulatory approval.
Biomedical award for rocket scientist
A Queensland rocket scientist turned bioengineer has claimed the $25,000 CSL Young Florey Medal.
Get me out of this wet suit!
The Age worries about Wonder Woman at the UN, but what about the Saudis?
CSL takes first strike on pay
CSL shareholders have lodged a protest vote over remuneration after CEO Paul Perreault’s pay surged to nearly $11m.
CSL faces suit in royalties row
Biotech giant CSL has been taken to court in the US accused of failing to pay royalties on a key drug.
Blood in water from paper cut
CSL chief Paul Perreault says there’s a pattern to the blood therapeutics group’s profit disclosures.
CSL takes its medicine
CSL chief Paul Perreault has pushed aside concern about its new flu business, saying it is well positioned for growth.
Behind the market’s CSL surprise
It seems the market hasn’t come to grips with the fact that CSL doesn’t play the normal game.
Out of sorts on CSL
Not everything is going CSL’s way, but neither is the diagnosis woeful.
Flu vaccine buy hits CSL result
CSL shares slumped after the purchase of the Novartis influenza vaccine helped cut its annual profit 10pc.
CSL outshines global peers
The biotech’s price is now at a record premium to global peers, despite earnings per share revisions.
Stocks soar on RBA’s move
The bourse has closed more than 2pc stronger, returning to its highest level in seven-and-a-half months.
Pollies take up case of sacked crew
MPs have vowed to interrogate the Coalition at Senate hearings after police forced sacked crew members off the CSL Melbourne yesterday.
New ship in foreign crew row
Crew members are refusing to sail a ship in “illegal industrial action’’ over coastal licences for foreign-crewed vessels.
CSL: Lamont named new finance chief
CSL has hired former BHP Billiton executive David Lamont as its new chief financial officer.
CSL soars after clotting advance
INVESTORS pushed CSL shares higher after it revealed plans to launch a new haemophilia drug in early 2016.
Reality check needed on climate deal
THE age of miracles is not over. Apparently, carbon dioxide emitted to industrialise is different from yours and mine.
CSL keen for Ebola treatment role
CSL has revealed it is in discussions with the World Health Organisation about Ebola treatment possibilities.
Biotechs: no cure without govt help
AUSTRALIA may lack the funds to spawn successors to biomedical high-flyers like Cochlear, CSL and Gardasil.
Wild ride
BMW’s X4 may not be as original or beautiful as a Range Rover Evoque, but it is one hell of a better drive.
Saying goodbye to carbon folly
LABOR’S leader must learn from his predecessors’ mistakes.
Nuclear power ‘could save reef’
ONE of Australia’s top marine scientists has teamed up with a nuclear engineer to address how nuclear power could save the Great Barrier Reef.
CO2 rise ‘to bring multiple droughts’
A CLIMATE phenomenon in the Indian Ocean linked with dry periods in Australia could nearly triple in frequency, a new paper suggests.
Original URL: https://www.theaustralian.com.au/topics/csl/page/11